References

Palchaudhuri R, Hyzy SL, Proctor JL, Adams HL, Pearse BR, Sarma G, Aslanian S, Gillard G, Lamothe TL, Burenkova O, Brooks ML, Gabros AD, McDonagh CF, Boitano AE, Cooke MP (2018) Antibody drug conjugates targeted to CD45 or CD117 enable allogeneic hematopoietic stem cell transplantation in animal models. Blood 132:3324. doi: 10.1182/blood-2018-99-119432

Objective: To further investigate and develop the utility of CD45-SAP and CD117-SAP, in combination with immunosuppression, in murine transplant models using i.v. administration in an allogeneic minor mismatch transplant model (Balb/c donor into DBA/2 recipients).

Summary: CD45-SAP or CD117-SAP in combination with immunosuppressants (30Fll and post-transplant Cytoxan) enabled >85% peripheral donor chimerism at 12 weeks post-transplantation. CD45-SAP and CD117-SAP were more effective at conditioning versus 2Gy TBI or pretransplant Cytoxan.

Usage: CD45-SAP (1.9 mg/kg, iv) and CD117-SAP (1mg/kg, iv) in an allogeneic minor mismatch transplant model (Balb/c donor into DBA/2 recipients).

Related Products: Streptavidin-ZAP (Cat. #IT-27)

Ostrin LA, Strang CE, Chang K, Jnawali A, Hung L-F, Arumugam B, Frishman LJ, Smith EL, Gamlin PD (2018) Immunotoxin-induced ablation of the intrinsically photosensitive retinal ganglion cells in rhesus monkeys. Front Neurol 9:1000. doi: 10.3389/fneur.2018.01000

Objective: To develop and validate a targeted ipRGC immunotoxin to ultimately examine the role of ipRGCs in macaque monkeys.

Summary: Findings demonstrated that Melanopsin-SAP was specific for ipRGCs, and induced a graded reduction in the PLR (pupillary light reflex), as well as in ipRGC-driven pupil response with concentration.

Usage: Solutions of 0.316, 1, 3.16, 10, and 50 μg delivered intravitreally.

Related Products: Melanopsin-SAP (Cat. #IT-44)

Fujii S, Yoshida S, Inagaki E, Hatou S, Tsubota K, Takahashi M, Shimmura S, Sugita S (2019) Immunological properties of neural crest cells derived from human induced pluripotent stem cells. Stem Cells Dev 28(1):28-43. doi: 10.1089/scd.2018.0058 PMID: 30251915

Objective: To assess the immunological properties of human induced pluripotent stem cells derived neural crest cells (iPSC-NCCs)

Summary: Cultured human NCCs can fully suppress T cell activation in vitro and may be used in cell-based medicine.

Usage: IHC; 1:200 dilution

Related Products: NGFr (ME20.4, p75) Mouse Monoclonal (Cat. #AB-N07)

Qiu M, Li J, Tan L, Zhang M, Zhou G, Zeng T, Li A (2018) Targeted ablation of distal cerebrospinal fluid-contacting nucleus alleviates renal fibrosis in chronic kidney disease. Front Physiol 9:1640. doi: 10.3389/fphys.2018.01640

Objective: To test the hypothesis that distal cerebrospinal fluid-contacting nucleus (dCSF-CNs) might affect the renin-angiotensin system (RAS) in kidney injury progression.

Summary: Less CTB-labeled neurons were found in dCSF-CNs of CTB-SAP-treated rats. Meanwhile, CTB-SAP downregulated AGT, Ang II, AT1R, NOX2, catalase, MCP-1, IL-6, fibronectin, and collagen I, and upregulated ACE2 and Mas receptor. Targeted dCSF-CNs ablation could alleviate renal inflammation and fibrosis in chronic kidney injury.

Usage: CTB-SAP (500 ng) into the lateral ventricles over a 3-min period.

Related Products: CTB-SAP (Cat. #IT-14)

Bailey D, Catron M, Kovtun O, Macdonald R, Zhang Q, Rosenthal S (2018) Single quantum dot tracking reveals serotonin transporter diffusion dynamics are correlated with cholesterol-sensitive threonine 276 phosphorylation status in primary midbrain neurons. ACS Chem Neurosci 9:2534-2541. doi: 10.1021/acschemneuro.8b00214 PMID: 29787674

Objective: Visualizing SERT behavior at the single molecule level in endogenous systems remains a challenge. The authors utilize quantum dot (QD) single particle tracking (SPT) to capture SERT dynamics in primary rat midbrain neurons.

Summary: Results provide new insights into endogenous neuronal SERT mobility and its associations with membrane cholesterol and SERT phosphorylation status.

Usage: Live Cell QD Tracking – Cells were incubated with 5 μg/mL primary SERT antibody in warm fluorescent media at 37 °C and 5% CO2 for 6 min.

Related Products: SERT Mouse Monoclonal (Cat. #AB-N40)

Manzuoerh R, Farahpour MR, Oryan A, Sonboli A (2019) Effectiveness of topical administration of Anethum graveolens essential oil on MRSA-infected wounds. Biomed Pharmacother 109:1650-1658. doi: 10.1016/j.biopha.2018.10.117 PMID: 30551419

Usage: immunohistochemistry (1:500)

Related Products: Fibroblast Growth Factor Rabbit Polyclonal, mammalian (Cat. #AB-07)

Seel S, Eacott M, Langston R, Easton A (2018) Cholinergic input to the hippocampus is not required for a model of episodic memory in the rat, even with multiple consecutive events. Behav Brain Res 354:48-54. doi: 10.1016/j.bbr.2017.06.001

Summary: The authors use 192-IgG-SAP (Cat. #IT-01) to examine episodic memory. Continual trials versions of an episodic memory task are unimpaired by cholinergic lesions of the medial septum. In contrast continual trial versions of a location-context (where-which) task are impaired in the same animals. The results replicate the effects of lesions on one-trial a day versions of the same tasks. Increasing the amount of interference between trials by increasing the overlap of features in consecutive events has no effect on the behavioural outcome of these lesions. The result is interpreted in light of models of acetylcholine function centered around pattern separation.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Shibata S, Hayashi R, Okubo T, Kudo Y, Katayama T, Ishikawa Y, Toga J, Yagi E, Honma Y, Quantock AJ, Sekiguchi K, Nishida K (2018) Selective laminin-directed differentiation of human induced pluripotent stem cells into distinct ocular lineages. Cell Rep 25:1668-1679. doi: 10.1016/j.celrep.2018.10.032 PMID: 30404017

Usage: Immunostaining, flow cytometry

Related Products: NGFr (ME20.4, p75) Mouse Monoclonal (Cat. #AB-N07)

Ueda H, Neyama H, Nagai J, Matsushita Y, Tsukahara T, Tsukahara R (2018) Involvement of lysophosphatidic acid-induced astrocyte activation underlying the maintenance of partial sciatic nerve injury-induced neuropathic pain. Pain 159:2170-2178. doi: 10.1097/j.pain.0000000000001316

Related Products: Mac-1-SAP mouse/human (Cat. #IT-06)

Daripelli S, Bhayrapuneni G, Tirumalesetty C, Benade V, Subramanian R, Petlu S, Praveena N, Jayarajan P, Shinde A, Badange R, Bhatta V, Nirogi R (2018) SUVN-G3031, H3 receptor inverse agonist produces wake promoting activity in rats with hypocretin-2-saporin lesions of the lateral hypothalamus. Neuroscience 2018 Abstracts 679.23 / VV4. Society for Neuroscience, San Diego, CA.

Summary: Numerous studies have demonstrated that brain histamine plays a crucial role in maintenance of wakefulness, attention, learning and other cognitive processes. SUVN-G3031, a potent H3 receptor inverse agonist is being developed for the treatment of narcolepsy and other sleep related disorders. SUVN-G3031 is one of the lead molecules with hKi of 8.7 nM and has more than 100 fold selectivity against the related GPCRs. SUVN-G3031 exhibited desired pharmacokinetic properties and brain penetration. SUVN-G3031 blocked R-α-methylhistamine induced water intake and increased tele-methylhistamine levels in brain and cerebrospinal fluid. A single oral administration of SUVN-G3031 produced significant increase in acetylcholine, histamine, dopamine and norepinephrine levels in the cortex. SUVN-G3031 produced wake promoting activity in male Wistar rats. In the present study, effects of SUVN-G3031 on sleep/ wake profile were evaluated in rats with lateral hypothalamic lesion using neurotoxin hypocretin-2-saporin. Narcoleptic-like sleep behavior was observed in rats injected with hypocretin-2-saporin in lateral hypothalamus. SUVN-G3031 produced significant increase in wakefulness with concomitant decrease in rapid eye movement (REM) sleep in these animals. These results are in agreement with electroencephalography (EEG) studies carried out in healthy male Wistar rats. Results from the current study and the neurotransmitter modulations produced by SUVN-G3031 provide a strong basis for the potential of SUVN-G3031 in treatment of sleep related disorders. First in human, Phase 1 studies for SUVN-G3031 are completed underUS IND and SUVN-G3031 has shown desirable pharmacokinetic profile with safety and tolerability in healthy human volunteers. Phase 2 study for narcolepsy is currently being planned.

Related Products: Orexin-B-SAP (Cat. #IT-20)